FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 33, Issue 1, Pages 99-106
Publisher
Elsevier BV
Online
2021-10-22
DOI
10.1016/j.annonc.2021.10.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
- (2021) Florentia Dimitriou et al. EUROPEAN JOURNAL OF CANCER
- The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis
- (2021) Judith M. Versluis et al. EUROPEAN JOURNAL OF CANCER
- CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
- (2021) Jedd D. Wolchok et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
- (2020) C.N. Owen et al. ANNALS OF ONCOLOGY
- Predictive value of FDG-PET imaging for relapse in metastatic melanoma patients treated with immunotherapy
- (2020) C. Mesnard et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
- (2019) Y J L Jansen et al. ANNALS OF ONCOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma
- (2018) J Lewin et al. ANNALS OF ONCOLOGY
- Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports
- (2018) Stefan Schliep et al. Journal for ImmunoTherapy of Cancer
- FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
- (2018) A C Tan et al. ANNALS OF ONCOLOGY
- Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.
- (2018) Shelly Ann Christiansen et al. JOURNAL OF CLINICAL ONCOLOGY
- 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.
- (2018) Omid Hamid et al. JOURNAL OF CLINICAL ONCOLOGY
- The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy
- (2017) Annie N. M. Wong et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy
- (2016) Benjamin Y. Kong et al. Pigment Cell & Melanoma Research
- Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment
- (2015) J. V. Cohen et al. Cancer Immunology Research
- Glucose Metabolism Regulates T Cell Activation, Differentiation, and Functions
- (2015) Clovis S. Palmer et al. Frontiers in Immunology
- Early and Late Therapy Response Assessment With [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial
- (2009) Christian Furth et al. JOURNAL OF CLINICAL ONCOLOGY
- Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
- (2008) C. Kobe et al. BLOOD
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search